DS-1062, a TROP2-targeting ADC with a Novel DNA Topoisomerase Inhibitor

Time: 9:10 am
day: Day One

Details:

  • DXd-ADC: Widely applicable technology platform
  • Preclinical results on the mechanism of action of DS-1062
  • Updates on clinical development of DS-1062

Speakers:

Daisuke Okajima
Daisuke Okajima

Daisuke Okajima received his master’s degree in Agriculture from Kyoto University and joined Daiich Pharmaceutical Co., Ltd. in 2001. He received his Ph.D. in Bioscience from Tsukuba University in 2011 and has been working on ADC research at Daiichi Sankyo Co., Ltd. since 2012. Now he is a representative of preclinical pharmacology in DS-1062 project,…Read more